Research Analysts Offer Predictions for ABIVAX Société Anonyme’s FY2024 Earnings (NASDAQ:ABVX)

ABIVAX Société Anonyme (NASDAQ:ABVX) – Stock analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for ABIVAX Société Anonyme in a report released on Monday, September 9th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.12) per share for the year, up from their previous estimate of ($3.35). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.80) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($3.47) EPS, FY2027 earnings at ($3.28) EPS and FY2028 earnings at ($2.76) EPS.

A number of other research analysts have also recently issued reports on ABVX. BTIG Research assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, May 20th. They set a “buy” rating and a $43.00 price objective for the company. Laidlaw started coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, ABIVAX Société Anonyme has an average rating of “Moderate Buy” and an average price target of $36.50.

ABIVAX Société Anonyme Stock Down 2.0 %

ABIVAX Société Anonyme stock opened at $11.72 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.08 and a current ratio of 3.04. The business has a 50-day moving average of $12.03 and a 200-day moving average of $13.46. ABIVAX Société Anonyme has a 1 year low of $7.99 and a 1 year high of $17.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ABVX. Blackstone Inc. acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $25,345,000. Commodore Capital LP acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth $20,277,000. Great Point Partners LLC bought a new stake in ABIVAX Société Anonyme during the fourth quarter worth $16,585,000. Franklin Resources Inc. acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $13,630,000. Finally, Rosalind Advisors Inc. bought a new position in shares of ABIVAX Société Anonyme in the 1st quarter valued at about $5,411,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.